Browsing tag


MAKE this a better outcome

The PRESERVE Trial, which was recently published in the NEJM was a large study of a variety of preventive measures for contrast-induced nephropathy. It used a 2×2 factorial design to test the efficacy of NaHCO3 vs. normal saline…

1557 0


A few months ago, a paper was published in the International Journal of Epidemiology that caused a sensation in it’s home country – Denmark. Using registry data, and the diagnosis of non-melanomatous skin cancer as a proxy for…

1106 1

Screening for CKD – The new ACP guidelines – Part 3

Recommendation 3: The ACP recommends that clinicians select pharmacologic therapy that includes either an angiotensin-converting enzyme inhibitor (moderate-quality evidence) or an angiotensin II-receptor blocker (high-quality evidence) in patients with hypertension and stage 1 to 3 chronic kidney disease….

875 2

Hemodialysis vs. Peritoneal Dialysis

My attention was caught by the recent article in CJASN which compared the mortality of peritoneal dialysis (PD) and hemodialysis (HD) patients in the first 2 years of dialysis therapy. When comparing survival outcomes of PD and HD…

6096 1

Time for a change?

This month’s issue of NDT has an interesting debate concerning whether or not clinical laboratories should start reporting CKD-EPI GFR instead of MDRD. The pro side is here while the con side is here. Basically, the argument for…

974 2

Falsification Analysis

Interesting paper this month in JAMA about post-marketing studies of adverse drug effects. Randomized controlled trials are obviously the gold standard for the detection of common adverse events related to treatment. The problem is that, if an adverse…

1560 0

Miracle Drug?

The above figure compares long term survival in a subgroup of a trial that was published in Circulation in 1980. This was a randomized controlled trial of just over 1000 patients with known cardiovascular disease who were treated with medical…

1269 0
Load more